Segment Data

3 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Segment Data

Segment DataThe Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.

Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended December 31,
(Millions of dollars)	2021						2020
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions	$	619	$	465	$	1,084	$	568	$	440	$	1,008
Medication Management Solutions	484		143		627		477		152		630
Diabetes Care	151		138		289		150		136		285
Pharmaceutical Systems	102		294		397		79		260		339
Total segment revenues	$	1,357	$	1,040	$	2,397	$	1,274	$	988	$	2,261
Life Sciences
Integrated Diagnostic Solutions	$	615	$	530	$	1,145	$	1,014	$	653	$	1,667
Biosciences	129		209		338		120		192		312
Total segment revenues	$	744	$	739	$	1,483	$	1,134	$	845	$	1,979
Interventional
Surgery	$	281	$	80	$	361	$	262	$	70	$	332
Peripheral Intervention	217		197		413		232		193		426
Urology and Critical Care	254		87		340		228		89		317
Total segment revenues	$	752	$	363	$	1,115	$	722	$	353	$	1,075
Total Company revenues	$	2,853	$	2,143	$	4,995	$	3,130	$	2,186	$	5,315

Segment income for the three-month periods was as follows:

	Three Months Ended December 31,
(Millions of dollars)	2021		2020
Income Before Income Taxes
Medical	$	716	$	666
Life Sciences	534		972
Interventional	265		302
Total Segment Operating Income	1,514		1,940
Acquisitions and other restructurings	(34)		(50)
Unallocated other operating expense, net (a)	(25)		—
Net interest expense	(96)		(116)
Other unallocated items (b)	(636)		(616)
Total Income Before Income Taxes	$	723	$	1,157

(a)The amount for the three-months ended December 31, 2021 includes $25 million of costs incurred for consulting, legal, tax and other advisory services associated with the planned spin-off of BD's Diabetes Care business.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.